Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 Combined with Afatinib or Osimertinib in EGFR Exon 20 Insertion NSCLC
NCT04448379Phase 1Unknown
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of becotatug in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Incidence of Adverse Events. Status: unknown.
02
Drugs
becotatug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04448379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04448379.